Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

MILAN, Oct. 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

"It's been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer," said Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year's ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types."

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 95 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patien
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... N.C. , July 23 Sales executives agree that ... process. Yet only 6 percent of district sales managers currently understand ... , , , ... knowledge of health outcomes, evidence based medicine and reimbursement," states an ...
... July 23 The North Shore-LIJ Health System Department of ... oropharynx (back of the mouth) to participate in a Phase I clinical ... Subjects must be ... must be unassociated with the human papilloma virus (HPV-negative), or, if it ...
Cached Medicine Technology:Health Outcomes Data Essential to Biopharmaceutical Sales Process 2Health Outcomes Data Essential to Biopharmaceutical Sales Process 3Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer 2
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... Sept. 17 Adlyfe, a private company,developing novel ... announced today that it has appointed Roxanne Duan, ... be responsible for overseeing,the Adlyfe,s Research efforts and ... Duan comes to Adlyfe with nearly two decades ...
... Symmetry Medical Inc.,(NYSE: SMA ), an ... industry and other medical markets, announced today the ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... provides easy to,find product information and a streamlined ...
... affect asthma type, study concludes, , , MONDAY, Sept. ... affect the type of asthma you develop, new ... youngsters in affluent, developed countries had more allergy-triggered ... developed countries. , "The link between atopic ...
... available, researchers must recruit hundreds or thousands of patients ... patients is often difficult. Many potential candidates are unaware ... logistical hurdles. As a result, patients miss out on ... therapies take longer to reach the public., In a ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... largest public health challenges, including AIDS, should be part of Presidential ... ... plans, WASHINGTON, Sept. 17 More than 100,organizations ... to ending the AIDS epidemic in America. They have requested that,every ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... A simple, effective method for determining color ... reliable data which can be applied to ... The set consists of four trays containing ... caps that have incremental hue variation on ...
... Farnsworth 100 Hue Test including MS-Excel scoring template ... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... test from Richmond Products includes 93 color discs, ...
... modification of the Farnsworth-Munsell 100 Hue Test. It ... the in-depth study of a color vision defect. ... ease or difficulty in distinguishing color differences in ... 15 color reference caps with Munsell notations, plus ...
Medicine Products: